Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding and bridging study of sugammadex for reversal of neuromuscular blockade (Caucasian subjects, Part B)
2005-001133-15Phase 2Completed
- Sponsor
- Organon & Co.
- Start
- Jul 2005
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Sugammadex in neuromuscular block (NMB) (5 arms), sponsored by Organon & Co. Primary endpoint: Time to recovery of T4/T1 ratio to 0.9. Started Jul 2005; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2005-001133-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001133-15.